$274.26
+2.04
(+0.75%)▲
Insights on United Therapeutics Corporation
Revenue is up for the last 6 quarters, 491.5M → 677.7M (in $), with an average increase of 6.1% per quarter
Netprofit is up for the last 2 quarters, 217.1M → 306.6M (in $), with an average increase of 29.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 56.5% return, outperforming this stock by 30.0%
1.45%
Downside
Day's Volatility :1.52%
Upside
0.07%
25.46%
Downside
52 Weeks Volatility :25.66%
Upside
0.27%
Period | United Therapeutics Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 28.06% | 0.5% | 0.0% |
6 Months | 19.77% | 14.1% | 0.0% |
1 Year | 26.51% | 11.9% | 0.0% |
3 Years | 54.23% | 18.7% | -20.0% |
Market Capitalization | 12.2B |
Book Value | $120.76 |
Earnings Per Share (EPS) | 21.12 |
PE Ratio | 12.99 |
PEG Ratio | 7.8 |
Wall Street Target Price | 300.95 |
Profit Margin | 42.05% |
Operating Margin TTM | 52.58% |
Return On Assets TTM | 12.25% |
Return On Equity TTM | 20.08% |
Revenue TTM | 2.5B |
Revenue Per Share TTM | 53.18 |
Quarterly Revenue Growth YOY | 33.7% |
Gross Profit TTM | 1.8B |
EBITDA | 1.3B |
Diluted Eps TTM | 21.12 |
Quarterly Earnings Growth YOY | 0.27 |
EPS Estimate Current Year | 24.24 |
EPS Estimate Next Year | 26.46 |
EPS Estimate Current Quarter | 5.65 |
EPS Estimate Next Quarter | 6.09 |
What analysts predicted
Upside of 9.73%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↓ 5.65% |
Net Income | 589.2M | ↑ 40.99% |
Net Profit Margin | 36.2% | ↑ 11.98% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | ↓ 11.0% |
Net Income | -104.5M | ↓ 117.74% |
Net Profit Margin | -7.21% | ↓ 43.41% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 2.38% |
Net Income | 514.8M | ↓ 592.63% |
Net Profit Margin | 34.71% | ↑ 41.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 13.63% |
Net Income | 475.8M | ↓ 7.58% |
Net Profit Margin | 28.23% | ↓ 6.48% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 14.88% |
Net Income | 727.3M | ↑ 52.86% |
Net Profit Margin | 37.56% | ↑ 9.33% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | ↑ 20.2% |
Net Income | 984.8M | ↑ 35.4% |
Net Profit Margin | 42.31% | ↑ 4.75% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 491.5M | ↓ 4.75% |
Net Income | 132.1M | ↓ 44.8% |
Net Profit Margin | 26.88% | ↓ 19.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 506.9M | ↑ 3.13% |
Net Income | 240.9M | ↑ 82.36% |
Net Profit Margin | 47.52% | ↑ 20.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 596.5M | ↑ 17.68% |
Net Income | 259.2M | ↑ 7.6% |
Net Profit Margin | 43.45% | ↓ 4.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 609.4M | ↑ 2.16% |
Net Income | 267.6M | ↑ 3.24% |
Net Profit Margin | 43.91% | ↑ 0.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 614.7M | ↑ 0.87% |
Net Income | 217.1M | ↓ 18.87% |
Net Profit Margin | 35.32% | ↓ 8.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 677.7M | ↑ 10.25% |
Net Income | 306.6M | ↑ 41.23% |
Net Profit Margin | 45.24% | ↑ 9.92% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | ↑ 18.11% |
Total Liabilities | 612.4M | ↓ 21.24% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.9B | ↑ 15.07% |
Total Liabilities | 1.1B | ↑ 85.01% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.6B | ↑ 17.93% |
Total Liabilities | 1.2B | ↑ 7.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 5.2B | ↑ 12.01% |
Total Liabilities | 1.2B | ↓ 0.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.0B | ↑ 16.94% |
Total Liabilities | 1.2B | ↑ 3.11% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 7.2B | ↑ 18.57% |
Total Liabilities | 1.2B | ↓ 5.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.0B | ↑ 4.55% |
Total Liabilities | 1.2B | ↑ 2.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↑ 4.99% |
Total Liabilities | 1.2B | ↓ 2.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.7B | ↑ 5.28% |
Total Liabilities | 1.3B | ↑ 3.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.0B | ↑ 5.12% |
Total Liabilities | 1.3B | ↑ 3.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.2B | ↑ 2.04% |
Total Liabilities | 1.2B | ↓ 9.86% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↓ 9.37% |
Total Liabilities | 1.2B | ↓ 2.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 778.4M | ↑ 64.15% |
Investing Cash Flow | -820.6M | ↓ 1.8% |
Financing Cash Flow | 6.3M | ↓ 85.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -206.6M | ↓ 126.54% |
Investing Cash Flow | -335.4M | ↓ 59.13% |
Financing Cash Flow | 611.2M | ↑ 9601.59% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 755.7M | ↓ 465.78% |
Investing Cash Flow | -738.5M | ↑ 120.18% |
Financing Cash Flow | -16.9M | ↓ 102.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 598.2M | ↓ 20.84% |
Investing Cash Flow | -486.9M | ↓ 34.07% |
Financing Cash Flow | 44.8M | ↓ 365.09% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 802.5M | ↑ 34.15% |
Investing Cash Flow | -811.5M | ↑ 66.67% |
Financing Cash Flow | 75.4M | ↑ 68.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 128.2M | ↓ 50.43% |
Investing Cash Flow | -189.3M | ↑ 101.38% |
Financing Cash Flow | 55.5M | ↑ 692.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 374.8M | ↑ 192.36% |
Investing Cash Flow | -221.1M | ↑ 16.8% |
Financing Cash Flow | 48.6M | ↓ 12.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 106.3M | ↓ 71.64% |
Investing Cash Flow | -227.2M | ↑ 2.76% |
Financing Cash Flow | 24.7M | ↓ 49.18% |
Sell
Neutral
Buy
United Therapeutics Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
United Therapeutics Corporation | 15.76% | 19.77% | 26.51% | 54.23% | 54.23% |
Moderna, Inc. | 30.29% | 68.31% | 6.04% | -16.69% | 488.05% |
Regeneron Pharmaceuticals, Inc. | 9.88% | 22.54% | 31.41% | 90.29% | 224.65% |
Novo Nordisk A/s | 7.45% | 27.32% | 56.5% | 231.22% | 458.15% |
Vertex Pharmaceuticals Incorporated | 13.15% | 24.76% | 31.15% | 107.42% | 168.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
United Therapeutics Corporation | 12.99 | 12.99 | 7.8 | 24.24 | 0.2 | 0.12 | NA | 120.76 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.04 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.57 | 28.57 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.03 | 46.03 | 2.36 | 3.47 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.58 | 28.58 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
United Therapeutics Corporation | Buy | $12.2B | 54.23% | 12.99 | 42.05% |
Moderna, Inc. | Buy | $50.8B | 488.05% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $106.7B | 224.65% | 28.57 | 29.45% |
Novo Nordisk A/s | Buy | $593.5B | 458.15% | 46.03 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $113.7B | 168.64% | 28.58 | 39.46% |
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
venBio Select Advisor LLC
FMR Inc
Renaissance Technologies Corp
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Organization | United Therapeutics Corporation |
Employees | 1168 |
CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
Industry | Health Technology |
Ppg Industries Inc.
$274.26
+0.75%
Microsectors Energy 3x Inverse Leveraged Notes Due January 29 2043
$274.26
+0.75%
Core Msci Total Intl Stk Ishares Etf
$274.26
+0.75%
Wec Energy Group, Inc.
$274.26
+0.75%
Paychex, Inc.
$274.26
+0.75%
Celanese Corporation
$274.26
+0.75%
Restaurant Brands International
$274.26
+0.75%
Rio Tinto Plc
$274.26
+0.75%
Thomson Reuters Corp.
$274.26
+0.75%